Clinical Trials Directory

Trials / Completed

CompletedNCT01083342

High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study

Open-labeled, Multicenter Phase II Study of High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Samsung Medical Center · Academic / Other
Sex
All
Age
20 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the complete response (CR) rate after HD-MTX induction chemotherapy followed by alternative HD MTX-based and HD Cytarabine-based combination consolidation chemotherapy

Conditions

Interventions

TypeNameDescription
DRUGMTX, MVD, VIAMTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)

Timeline

Start date
2010-01-01
Primary completion
2012-05-01
Completion
2012-05-01
First posted
2010-03-09
Last updated
2012-05-24

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01083342. Inclusion in this directory is not an endorsement.

High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Co (NCT01083342) · Clinical Trials Directory